Commentary

Heterogeneity of Drug Target Expression Among Metastatic Lesions: Lessons from a Breast Cancer Autopsy Program

Patricia S. Steeg

The target tissue for most cancer therapeutics is metastatic disease, either the treatment of overt metastases or the prevention of colonization by micrometastases in the adjuvant setting. Despite this, few drugs are tested in the metastatic setting in preclinical experiments, and relatively little is known about the expression of therapeutic targets in human metastases. A firestorm was ignited by several reports in which paired primary breast tumors and metastases were profiled by gene expression microarrays. Paired samples clustered together using multiple bioinformatic methods, suggesting little variation in gene expression patterns (1–3). Other reports using the same type of analysis identified alterations in gene expression between paired primary tumors and either lymph node or distant metastases (4–8). These reports are supplemented by studies at the protein level indicating a myriad of expression differences between primary tumors and matched metastases (reviewed in ref. 9, Supplementary Table S1). Whether there is a difference in molecular profile between primary tumors and their metastasis is not strictly an academic question, considering the fact that there is a growing belief that molecular target expression data should be used to enter patients onto clinical trials. Is the information provided by a primary tumor alone sufficient?

Wu et al. (10) recently analyzed tissues from rapid autopsies of 10 breast cancer patients, providing a wealth of data on therapeutic targets in the metastatic setting. The patients were roughly half lymph node positive versus negative at diagnosis; the mean interval between diagnosis and death was 6.3 years (range, 2-11). Metastatic tissue was harvested from four to seven independent lesions, which represents an advantage over most other studies that have compared a primary with a single-matched metastatic lesion. Tissues were obtained within 4 h of death and should also be suitable for high-quality RNA expression profiling.

Several trends observed in the expression of therapeutic targets are diagrammed on Fig. 1. With regard to estrogen receptor (ER), six of the primary tumors were positive; the remainder of the cases met criteria for triple-negative breast cancer. For the ER+ cases, the ER staining of the metastases was equivalent to that of the primary tumor in two cases, reduced (in terms of percentage of positive staining tumor cells) in two cases, and negative in the remaining two cases. Similar trends

have been reported previously in the literature, based on immunohistochemical analyses of primary tumors compared with a lymph node metastasis, in some (11–14) but not all (15, 16) articles. Progesterone receptor expression followed similar trends in the autopsy study, decreasing in the metastases from two cases and becoming negative in an additional two cases. Although many elegant pathways have been described for tamoxifen resistance, simple loss of hormone receptor expression must be considered another contributing factor.

The expression of several receptor tyrosine kinases was determined (10). Four of the ER⁻ primary tumors were positive for epidermal growth factor receptor (EGFR) by immunohistochemistry. In each case, heterogeneity was observed in EGFR levels among the metastases. Similarly, c-Met was expressed by immunohistochemistry in the four triple-negative cases. c-Met staining was consistent between primary tumors and metastases in two of these cases and heterogeneous in the remaining two cases, varying from 0 to 2+ in the metastases. Her-2 was unamplified in all primary tumors, thus limiting the analysis of this receptor tyrosine kinase. Fluorescence in situ hybridization data for the metastatic tissues were unamplified in the vast majority of cases but reached 3.0 in an omental sample from a single case.

Wu et al. (10) also presented a comprehensive analysis of the DNA methylation status of seven gene promoters. Relative concordance of promoter methylation status among primary tumors and multiple metastases was found for the *HIN1*, *Twist*, and *ERα* genes, whereas various degrees of discordance was found for *RASSF1A*, *Cyclin D2*, *APCc1*, and *RARβ* (Fig. 1). The data suggest that some genes may be more amenable to epigenetically based therapies than others.

Although the complete loss of a therapeutic target in a metastatic lesion makes sense as a potential determinant of drug response, what is the significance of a change from 2+ to 1+ intensity, for example? Few targets have been comprehensively examined for the relationship of quantitative expression to drug efficacy, yet the idea is attractive. One of the best examples is ER, where a quantitative Allred score has been developed. The Allred score reflects the percentage of positively staining tumor cells added to an average intensity score. This continuous score segregated patient disease-free survival to endocrine therapy, suggesting that intervals in expression may be biologically meaningful (17). In a neoadjuvant chemotherapy trial, the Allred score increased between biopsy and surgery in 49 of 296 breast cancer patients and was associated with improved disease-free survival but not overall survival (18). When ER was quantified by another multilevel algorithm, a shorter time to recurrence was associated with lower levels of ER in tamoxifen-treated ($P = 0.07$) and anastrozole-treated ($P = 0.009$) patients in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial (19). For EGFR, multiple metrics

ER+ Invasive Ductal Carcinoma

Triple-Negative Invasive Ductal Carcinoma

Primary tumor:
ER: 80%+
PR: 30%+
% Methylation:
 RASSF1A: 32
 CYCLIN D2: 0.8
 RARB : 7
 APC1: 0.8

Liver Mets:
ER: Negative
PR: Negative
% Methylation:
 RASSF1A: 26-50
 CYCLIN D2: 2-10
 RARB : 9-10
 APC1: 10-20

Bone Met:
ER: Negative
PR: Negative
% Methylation:
 RASSF1A: ~0
 CYCLIN D2: 0
 RARB : ~0
 APC1: ~0

Diaphram Met:
EGFR IHC: 1+
MET IHC: 2+
COX-2: Positive
% Methylation:
 RASSF1A: 95
 CYCLIN D2: 11
 APC1: 0
 RARB: 12

Liver Mets:
EGFR IHC: 1+
MET IHC: 1+
% Methylation:
 RASSF1A: 30-72
 CYCLIN D2: 7-12
 APC1: 14-34
 RARB : 12

Omental Met:
EGFR IHC: 1+
MET IHC: 2+
COX-2: Positive
% Methylation:
 RASSF1A: 69
 CYCLIN D2: 6
 APC1: 0
 RARB: 7

Lymph node:
EGFR IHC: 1+
MET IHC: 2+

Primary tumor:
EGFR IHC: 1+
MET IHC: 1+
COX-2: Negative
% Methylation:
 RASSF1A: 67
 CYCLIN D2: 0
 APC1: 6
 RARB: 8

Left Adrenal Met:
EGFR IHC: 2+
MET IHC: 1+
COX-2: Negative
% Methylation:
 RASSF1A: 89
 CYCLIN D2: 1
 APC1: 0
 RARB: 8

Bone Met:
EGFR IHC: 1+
MET IHC: 1+
COX-2: Negative
% Methylation:
 RASSF1A: 5
 CYCLIN D2: 2
 APC1: ~0
 RARB: ~0

Fig. 1. Representative cases from a rapid autopsy program (10). Metastases (*Met*) were harvested within 4 h of death from 10 patients and compared with the matched primary tumor. The results from two cases are diagrammed. Immunohistochemical (*IHC*) staining for ER and progesterone receptor (*PR*) is based on the percentage of positive cells, that for EGFR and c-Met (*MET*) is on a 0 to 3+ intensity scale, and cyclooxygenase-2 (*COX-2*) is positive/negative. Percentage DNA methylation of gene promoters was determined by quantitative multiplex methylation-specific PCR assay. Methylation of the *HIN1,Twist*, and *ERα* genes was relatively uniform in all samples.

of expression have been imperfectly correlated with therapeutic response, including protein expression, mutation, and gene amplification. Using immunohistochemistry, EGFR expression levels in lung cancer have been quantified as either positive or negative, and conflicting correlations have been obtained with response to kinase inhibitors (20). It will be of interest to determine the effect of target expression level, and heterogeneity of expression among lesions, on the efficacy of this and other therapeutic targets. Support for autopsy studies where samples can be analyzed from multiple metastases has been limited in recent years but may be a worthy adjunct to preclinical validation studies.

References

1. Weigelt B, Glas A, Wessels L, Witteveen A, Peterse J, van't Veer L. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003;100:15901–5.

2. Weigelt B, Hu Z, He X, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005;65:9155–8.

3. Weigelt B, Wessels LF, Bosma AJ, et al. No common denominator for breast cancer lymph node metastasis. Br J Cancer 2005;93:924–32.

4. Dupont VN, Gentien D, Oberkampf M, De Rycke Y, Blin N. A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients. Int J Cancer 2007;121:1036–46.

5. Suzuki M, Tarin D. Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: clinical implications. Mol Oncol 2007;1:172–80.

6. Hao X, Sun B, Hu L, et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 2004;100:1110–22.

7. Feng Y, Sun B, Li X, et al. Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat 2007; 103:319–29.

8. Vecchi M, Confalonieri S, Nuciforo P, et al. Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 2008;27:2148–58.

9. Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 2008;5: 206–19.

10. Wu JM, Fackler MJ, Halushka MK, et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008;14:1938–46.

11. Ding L, Sunamura M, Kodama T, et al. *In vivo* evaluation of the early events associated with liver metastasis of circulating cancer cells. Br J Cancer 2001;85: 431–8.

12. Dikicioglu E, Barutca S, Meydan N, Meteoglu I.

Biological characteristics of breast cancer at the primary tumour and the involved lymph nodes. Int J Clin Pract 2005;59:1039 – 44.

13. Koda M, Sulkowski S, Kanczuga-Koda L, Surmacz E, Sulkowska M. Expression of ERα, ERβ and Ki-67 in primary tumors and lymph node metastases in breast cancer. Oncol Rep 2004;11:753 – 9.

14. Iguchi C, Nio Y, Itakura M. Heterogeneic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome. J Surg Oncol 2003; 83:85 – 93.

15. Kristek J, Dmitrovic B, Kurbel S, et al. Tumor growth fraction, expression of estrogen and progesterone

receptors, p53, bcl-2 and cathepsin D activity in primary ductal invasive breast carcinoma and their axillary lymph node metastases. Coll Antropol 2007;31: 1043 – 7.

16. van Agthoven T, Timmermans M, Dorssers LC, Henzen-Logmans SC. Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer. Int J Cancer 1995;63:790 – 3.

17. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474 – 81.

18. Tacca O, Penault-Llorca F, Abrial C, et al. Changes in

and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 2007;12: 636 – 43.

19. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:1059 – 65.

20. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983 – 94.

Clinical Cancer Research

Heterogeneity of Drug Target Expression Among Metastatic Lesions: Lessons from a Breast Cancer Autopsy Program

Patricia S. Steeg

Updated version	Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/14/12/3643

Cited articles	This article cites 20 articles, 7 of which you can access for free at: http://clincancerres.aacrjournals.org/content/14/12/3643.full#ref-list-1
Citing articles	This article has been cited by 3 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/14/12/3643.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/14/12/3643. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.